Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

Inclusion Criteria: * Age above 18 * Male or Female * Patients with Type II diabetes mellitus must be receiving oral agents or insulin injections at the time of randomization * All eligible patients will be on a stable, maximum to dose of an ACE or ARB for 2 weeks prior to randomization. * Note: The determination of m tolerated ACE-ARB therapy will be left to the discretion of the site princ * All eligible patientswill have hypertension targetblood pressur of \< 140/90mm Hg. * Antihypertensiv therapy may be adjusted to achieve the target blood pressure prior to the time of randomization. * ACE or ARB therapy will be the primary antihypertensive therapy used for blood pressure control and will be titrthe highest tolerated dose to achieve a target blood pressure of \<Patients requiring additional medications to achieve the target blood pressure will use antihypertensive agents that have neutral effects on urinary proteinuria (e.g. Hydralazine or lo Dihydropyridine calcium channel blockers etc.). CcThe final choice of additional medications will be left to the discretion of the site principal investigator (PI) * Patients with anurine protein to creatinine (UP/Cr) ratio that is mg/gm from the average of two historical value within one year prior to randomization will be considered eligible for study entry. * Patients with a baseline K+ of \>5. X5 meq/l on maximum tolerated ACE-ARB therapy during the screening period can be treated with 8.4 grams of Patiromer for 7 days. If at th…